Every material Form 8-K Collegium Pharmaceutical filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Collegium entered a $980 million credit agreement on December 23, 2025, with Truist Bank as administrative agent. The facility includes a $580 million term loan, a $300 million delayed draw term loan, and a $100 million revolving credit facility, and the company used the initial term loan to repay its existing credit agreement in full. The new loans carry interest at SOFR plus 2.75% to 3.75%, based on the company's leverage ratio, and the company says the lower rate is expected to produce meaningful annualized interest savings.
The $980 million facility includes a $580 million term loan, $300 million delayed draw term loan and $100 million revolver, with the last two undrawn at closing.
The initial term loan repaid the remaining balance of the existing loan, which the press release cites as approximately $581 million of principal, with the prepayment premium and make-whole amount also paid.
Interest is term SOFR plus a spread of 2.75% to 3.75%, based on the First Lien Net Leverage Ratio; the rate at closing was SOFR plus 2.75%.
Scheduled quarterly repayments begin March 31, 2026, and the company may repay the loans at any time without premium or penalty; the facility matures in 2030.
Collegium Pharmaceutical reported third-quarter 2025 results on November 6, 2025, with product revenues, net of $209.4 million, up 31% from a year earlier, and GAAP diluted earnings of $0.84 per share versus $0.27. The company raised its full-year 2025 product revenue guidance to $775 million to $785 million and its adjusted EBITDA guidance to $460 million to $470 million, which supports the outlook for shareholders.
Q3 2025 product revenues, net were $209.4 million versus $159.3 million in Q3 2024; Jornay PM net revenue was $41.8 million.
GAAP net income was $31.5 million, or $0.84 diluted EPS, versus $9.3 million, or $0.27, a year earlier; adjusted EPS was $2.25 versus $1.61.
Full-year 2025 product revenue guidance was raised to $775 million to $785 million from $745 million to $760 million; adjusted EBITDA guidance was raised to $460 million to $470 million from $440 million to $455 million.
Board authorized a share repurchase program of up to $150 million through December 31, 2026; cash, cash equivalents and marketable securities were $285.9 million at quarter end.
Collegium reported second-quarter 2025 product revenue of $188.0 million, up 29% from a year earlier, and raised its full-year 2025 product revenue guidance to $745 million to $760 million. GAAP net income fell to $12.0 million, or $0.34 per diluted share, from $19.6 million, or $0.52, a year earlier, as operating expenses rose. The company also authorized a $150 million share repurchase program running through December 31, 2026.
Q2 2025 product revenue of $188.0 million, up 29% year over year; Jornay PM net revenue of $32.6 million, with prescriptions up 23%
Full-year 2025 product revenue guidance raised to $745 million to $760 million, from $735 million to $750 million; adjusted EBITDA guidance raised to $440 million to $455 million
GAAP net income of $12.0 million ($0.34 diluted EPS) for Q2 2025, versus $19.6 million ($0.52) for Q2 2024
Board authorized a $150 million share repurchase program through December 31, 2026; cash and marketable securities were $222.2 million at June 30, 2025
At its May 15, 2025 annual meeting, Collegium Pharmaceutical shareholders elected all eight director nominees and approved the 2025 Equity Incentive Plan, which allows stock-based awards to officers, directors and employees. Shareholders also approved executive pay on an advisory basis and chose annual advisory votes on pay, and ratified Deloitte & Touche LLP as auditor for 2025.
Plan approval: 20,255,783 for, 7,143,482 against, 245,956 abstentions, 1,449,301 broker non-votes
Eight directors elected to serve until the 2026 Annual Meeting; Nancy Lurker received 25,089,514 for votes
Shareholders preferred an advisory pay vote every one year (26,389,740 votes)
29,094,522 of 32,131,798 eligible shares were present in person or by proxy
Collegium reported first-quarter 2025 product revenues, net of $177.8 million, up 23% from a year earlier, and reaffirmed its full-year 2025 guidance. GAAP net income fell to $2.4 million from $27.7 million, while adjusted earnings per share rose to $1.49 from $1.45, so shareholders face higher revenue alongside a sharp drop in reported profit. The board also authorized a $25.0 million accelerated share repurchase program.
Product revenues, net rose 23% to $177.8 million from $144.9 million in the first quarter of 2024.
GAAP net income was $2.4 million, or $0.07 diluted EPS, versus $27.7 million, or $0.71, a year earlier; intangible asset amortization and impairment was $55.5 million.
Adjusted EPS was $1.49 versus $1.45, and adjusted EBITDA was $95.2 million versus $92.4 million.
The company reaffirmed 2025 product revenues, net guidance of $735.0 million to $750.0 million and authorized a $25.0 million accelerated share repurchase.
Collegium Pharmaceutical said founder and Chairman Michael Heffernan and director Gwen Melincoff will not stand for re-election at the 2025 Annual Meeting. The board named lead independent director Gino Santini as Chairman effective after that meeting, and the company said the departures are part of board refreshment and succession planning, not a disagreement. The filing also announced David Dieter as Executive Vice President and General Counsel, effective March 17, 2025.
Michael Heffernan, founder and Chairman, advised the board on March 11, 2025 that he will retire at the Annual Meeting; he has served on the board since October 2003
Gwen Melincoff, a director since 2017, will also retire at the Annual Meeting
Gino Santini, lead independent director since 2018, becomes Chairman effective immediately after the Annual Meeting
Dr. Carlos Paya was nominated on March 14, 2025 to stand for election at the Annual Meeting; David Dieter became General Counsel on March 17, 2025
Collegium reported record fourth-quarter and full-year 2024 product revenues and reaffirmed its 2025 guidance. Q4 GAAP net income fell to $12.5 million from $31.9 million a year earlier, though full-year GAAP net income rose to $69.2 million from $48.2 million. Shirley Kuhlmann, executive vice president, chief administrative officer, general counsel and secretary, will leave the company effective March 7, 2025.
Q4 product revenues, net were $181.9 million, up 22% from $149.7 million; Q4 GAAP diluted EPS was $0.36 versus $0.82 a year earlier
Full-year 2024 product revenues, net were $631.4 million, up 11%; full-year GAAP net income was $69.2 million versus $48.2 million
2025 guidance reaffirmed: product revenues, net of $735.0 to $750.0 million and adjusted EBITDA of $435.0 to $450.0 million
Shirley Kuhlmann steps down effective March 7, 2025; her departure is treated as a termination without cause under her existing employment agreement
Collegium Pharmaceutical's board expanded from eight to nine directors and appointed Nancy Lurker as a director effective February 4, 2025. Ms. Lurker is a former CEO of EyePoint Pharmaceuticals and previously held senior roles at Novartis and other pharmaceutical companies, and the filing states she is independent under Nasdaq rules.
Board expanded from eight to nine directors; Nancy Lurker appointed effective February 4, 2025
Lurker receives a $50,000 annual cash retainer, prorated, plus restricted stock units with a $412,500 grant date value
Her restricted stock units vest on the first anniversary of the grant, subject to continued service; her term runs to the 2025 Annual Meeting
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Collegium Pharmaceutical filing is on SEC EDGAR ↗. 8-K briefs of other companies →